P. Musto

480 total citations
18 papers, 227 citations indexed

About

P. Musto is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, P. Musto has authored 18 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in P. Musto's work include Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (4 papers). P. Musto is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (4 papers). P. Musto collaborates with scholars based in United States. P. Musto's co-authors include Narasimhan P. Agaram, Sunil Badve, Rutika Mehta, Thomas M. Ulbright, Muhammad T. Idrees, Kurt Hodges, Eyas M. Hattab, Andrew R. Branagan, Terenig Terjanian and Joseph J. Kash and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

P. Musto

18 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Musto United States 7 115 98 79 48 47 18 227
Vinciane Marchand France 9 164 1.4× 85 0.9× 25 0.3× 59 1.2× 106 2.3× 13 257
Gregory E. Otteson United States 8 110 1.0× 42 0.4× 23 0.3× 22 0.5× 67 1.4× 21 202
Ahmed M. Amer United States 7 44 0.4× 81 0.8× 19 0.2× 32 0.7× 125 2.7× 19 313
Melanie Zenger Germany 9 68 0.6× 120 1.2× 247 3.1× 80 1.7× 43 0.9× 29 335
Carmen Herling Germany 9 127 1.1× 182 1.9× 32 0.4× 74 1.5× 59 1.3× 23 320
María‐Teresa Cedena Spain 12 50 0.4× 114 1.2× 269 3.4× 159 3.3× 121 2.6× 36 405
Habte Yimer United States 9 78 0.7× 75 0.8× 136 1.7× 106 2.2× 156 3.3× 48 270
Haruka Ikoma Japan 11 225 2.0× 83 0.8× 5 0.1× 82 1.7× 141 3.0× 23 358
Martina Fröhlich Germany 7 41 0.4× 19 0.2× 35 0.4× 162 3.4× 73 1.6× 17 315

Countries citing papers authored by P. Musto

Since Specialization
Citations

This map shows the geographic impact of P. Musto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Musto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Musto more than expected).

Fields of papers citing papers by P. Musto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Musto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Musto. The network helps show where P. Musto may publish in the future.

Co-authorship network of co-authors of P. Musto

This figure shows the co-authorship network connecting the top 25 collaborators of P. Musto. A scholar is included among the top collaborators of P. Musto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Musto. P. Musto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
McClelland, Shearwood, Gregory A. Durm, Thomas J. Birdas, P. Musto, & Tim Lautenschlaeger. (2019). First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy. Reports of Practical Oncology & Radiotherapy. 24(6). 507–510. 1 indexed citations
2.
Mehta, Rutika, P. Musto, Kurt Hodges, et al.. (2011). Atypical ductal hyperplasia: interobserver and intraobserver variability. Modern Pathology. 24(7). 917–923. 84 indexed citations
3.
Palumbo, Antonio, Sara Bringhen, Sonja Zweegman, et al.. (2011). Secondary malignancies in elderly myeloma patients. Pure Amsterdam UMC. 96. 6 indexed citations
4.
Voso, Maria Teresa, Luana Fianchi, Marianna Criscuolo, et al.. (2011). 192 Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN). Leukemia Research. 35. S76–S76. 1 indexed citations
5.
Zupa, Angela, Giuseppina Improta, Michele Aieta, et al.. (2010). Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors.. Journal of Clinical Oncology. 28(15_suppl). 10594–10594. 2 indexed citations
6.
Improta, Giuseppina, Angela Zupa, Helen L. Fillmore, et al.. (2010). Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study.. Journal of Clinical Oncology. 28(15_suppl). 10620–10620. 1 indexed citations
7.
Boccadoro, Mario, Sara Bringhen, Gianluca Gaïdano, et al.. (2010). Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients.. Journal of Clinical Oncology. 28(15_suppl). 8013–8013. 2 indexed citations
8.
Sacchi, Stefano, Raffaella Marcheselli, Samantha Pozzi, et al.. (2009). A RANDOMIZED PHASE II STUDY (GISL-MM03 TRIAL) WITH ORAL MELPHALAN plus PREDNISONE (MP) VERSUS MELPHALAN, plus PREDNISONE plus THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. Iris Unimore (University of Modena and Reggio Emilia). 94. 384–384. 1 indexed citations
9.
Iacobelli, Stefano, Ute Hegenbart, Astrid Gruber, et al.. (2008). Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT. Bone Marrow Transplantation. 41. 1 indexed citations
10.
Treon, Steven P., Jacob D. Soumerai, Andrew R. Branagan, et al.. (2008). Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Research. 15(1). 355–360. 89 indexed citations
11.
Musto, P., Ilaria Avonto, Potito Rosario Scalzulli, et al.. (2006). INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA. 235–235. 1 indexed citations
12.
Palumbo, Antonio, Alessandra Bertola, P. Musto, et al.. (2004). Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma patients. Journal of Clinical Oncology. 22(14_suppl). 6549–6549. 6 indexed citations
13.
Bringhen, Sara, Alessandra Bertola, Federica Cavallo, et al.. (2003). TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS. Haematologica. 88. 17–18. 12 indexed citations
14.
Tosi, P., Elena Zamagni, Claudia Cellini, et al.. (2002). Salvage Therapy With Thalidomide In Patients With Advanced Relapsed/Refractory Multiple Myeloma. Journal of the Peripheral Nervous System. 7(3). 209–209. 8 indexed citations
15.
Palumbo, Antonio, Alessandra Bertola, Federica Cavallo, et al.. (2002). Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. 100. 1 indexed citations
16.
Palumbo, Antonio, S Triolo, Sara Bringhen, et al.. (2000). IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT. 96. 419–419. 1 indexed citations
18.
Musto, P., et al.. (1977). [An unusual case of postoperative mechanical obstruction of the upper respiratory tract in a child].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 43(3). 207–12. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026